n°222

January 2021

Issue Contents
Editorial

Free  A two-step approach

p.3

Marketing Authorisations

Esketamine (Spravato°) and "treatment-resistant" depression

p.5-9
Huge risks for uncertain efficacy

Editors' opinion. Misuse

p.8

Tafamidis (Vyndaqel°) and transthyretin amyloid cardiomyopathy

p.9-10

Voretigene neparvovec (Luxturna°) and certain forms of inherited retinal dystrophy

p.10-11
Improvement in navigational ability in dim light, but questions remain over the risks

INN Common stem: -steride

p.11

Free  Dasatinib (Sprycel° and other brands) in children with acute lymphoblastic leukaemia

p.12-13

Free  Editors' opinion. Failure to demand solid evidence for marketing authorisation spells danger for patients

p.13

Risankizumab (Skyrizi°) and plaque psoriasis

p.13

Romiplostim (Nplate°) and chronic immune thrombocytopenia from one year of age

p.13

Remdesivir (Veklury°) and covid-19

p.14-15
Too many uncertainties over its efficacy as well as its harms

Editors' opinion. Authorisation of remdesivir in the European Union: EMA needs to prioritise patients' interests

p.15

Adverse Effects

SSRI antidepressants and pregnancy: long-term neuropsychiatric disorders in exposed children? (continued)

p.16-18

Lamotrigine: very variable exposure in breastfed infants

p.19

NSAIDs: complications of sinusitis

p.19

Reviews

 Queries and Comments. Erythema migrans: what is the first-choice antibiotic?

p.20

Psoriatic arthritis and secukinumab

p.21
No better than adalimumab, and with more limited follow-up

Gout attack pain

p.22
Colchicine no more effective than naproxen

Outlook

 History(ies). The invention of antidepressants

p.23-25

Adverse effects and clinical trial results in oncology: misleading terms and omissions

p.26-27

Drug research and development: public investors with an ambivalent role

p.27

Masthead

Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe